Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy

NCT01075971 is registered in ClinicalTrials.gov with Indivior Inc. as lead sponsor.

NCT NCT01075971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01075971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy
Lead sponsor
Indivior Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
November 30, 2005
Enrollment
52 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

opioid dependency